• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NeuroMetrix Inc. (Amendment)

    2/14/22 6:56:51 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care
    Get the next $NURO alert in real time by email
    SC 13G/A 1 d304696dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    NeuroMetrix, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    641255807

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

      

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 641255807

     

      1    

      Names of reporting persons

     

      Topline Capital Management, LLC

      2  

      Check the appropriate box if a member of a group (see instructions)

     

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      California

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5    

      Sole voting power

     

      570,478

       6  

      Shared voting power

     

      0

       7  

      Sole dispositive power

     

      570,478

       8  

      Shared dispositive power

     

      0

      9    

      Aggregate amount beneficially owned by each reporting person

     

      570,478

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      8.1%

    12  

      Type of reporting person (see instructions)

     

      IA

     

    2


    CUSIP No. 641255807

     

      1    

      Names of reporting persons

     

      Collin McBirney

      2  

      Check the appropriate box if a member of a group (see instructions)

     

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      USA

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5    

      Sole voting power

     

      0

       6  

      Shared voting power

     

      570,478

       7  

      Sole dispositive power

     

      0

       8  

      Shared dispositive power

     

      570,478

      9    

      Aggregate amount beneficially owned by each reporting person

     

      570,478

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      8.1%

    12  

      Type of reporting person (see instructions)

     

      IN/HC

     

    3


    CUSIP No. 641255807

     

      1    

      Names of reporting persons

     

      Topline Capital Partners, LP

      2  

      Check the appropriate box if a member of a group (see instructions)

     

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5    

      Sole voting power

     

      570,478

       6  

      Shared voting power

     

      0

       7  

      Sole dispositive power

     

      570,478

       8  

      Shared dispositive power

     

      0

      9    

      Aggregate amount beneficially owned by each reporting person

     

      570,478

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      8.1%

    12  

      Type of reporting person (see instructions)

     

      PN

     

    4


    Item 1

    (a) Name of Issuer:

    NeuroMetrix, Inc.

    (b) Address of Issuer’s Principal Executive Offices:

    4B Gill Street, Woburn, MA 01801

    Item 2

    (a) Name of Persons Filing:

    Topline Capital Management, LLC (“TCM”)

    Collin McBirney

    Topline Capital Partners, LP (“TCP” or the “Fund”)

    (b) Address of Principal Business Office or, if none, Residence:

    544 Euclid Street, Santa Monica, CA 90402

    (c) Citizenship:

    Reference is made to Row 4 of pages 2 - 4 of this Schedule 13G (this “Schedule”), which are incorporated by reference herein.

    (d) Title of Class of Securities:

    Common Stock, $0.0001 par value

    (e) CUSIP Number: 641255807

    Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4. Ownership

    Reference is hereby made to Rows 5-9 and 11 of pages 2, 3 and 4 of this Schedule, which are incorporated by reference herein.

    As of December 31, 2021 and the date of this filing, the Fund beneficially owns 570,478 shares of the issuer’s common stock.

    The securities reported on this Schedule as beneficially owned by TCM (the “Securities”) are held by and for the benefit of the Fund. Under the definition of “beneficial ownership” in Rule 13d-3 under the Act, it is also possible that the individual general partners, executive officers, and members of the foregoing entities might be deemed the “beneficial owners” of some or all of the Securities insofar as they may be deemed to share the power to direct the voting or disposition of such Securities. TCM, as the investment manager and general partner of the Fund, and Collin McBirney, as the member-manager of TCM, may, therefore, be deemed to beneficially own the Securities held by the Fund for the purposes of Rule 13d-3 under the Act insofar as they may be deemed to have the power to direct the voting or disposition of those Securities.

    Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of TCM or Mr. McBirney is, for any other purpose, the beneficial owner of any of the Securities held by the Fund, and each of TCM and Mr. McBirney expressly disclaims beneficial ownership as to the Securities held by the Fund, except to the extent of its or his pecuniary interests therein.

     

    5


    The calculation of percentage of beneficial ownership in Row 11 of pages 2, 3 and 4 of this Schedule was derived from the issuer’s Form 10-K Annual Report filed with the Securities and Exchange Commission on January 28, 2022, in which the issuer stated that the number of shares of its common stock outstanding as of January 27, 2022 was 6,992,239 shares.

     

    6


    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2022

     

    TOPLINE CAPITAL MANAGEMENT, LLC
    By:  

    /s/ Collin McBirney

      Collin McBirney
      Managing Member
    TOPLINE CAPITAL PARTNERS, LP
    By:   Topline Capital Management, LLC,
      its general partner
    By:  

    /s/ Collin McBirney

      Collin McBirney
      Managing Member
    COLLIN MCBIRNEY

    /s/ Collin McBirney

     

    8


    EXHIBIT LIST

     

    Exhibit A    Joint Filing Undertaking
    Get the next $NURO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NURO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NURO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horowitz Joshua returned 90,307 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 6:51:59 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Goodman David returned 7,602 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:03 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Van Avermaete David returned 7,601 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:02 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    SEC Filings

    View All

    SEC Form 15-12G filed by NeuroMetrix Inc.

    15-12G - NeuroMetrix, Inc. (0001289850) (Filer)

    5/12/25 4:05:30 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:11 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:15 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroMetrix Inc.

    SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)

    9/27/24 3:56:52 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by NeuroMetrix Inc. (Amendment)

    SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)

    3/4/24 4:12:13 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by NeuroMetrix Inc.

    SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)

    2/27/24 4:00:09 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

    Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie

    4/19/24 8:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

    WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol

    9/1/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Appoints Brad Fluegel to its Board of Directors

    WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha

    6/28/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Financials

    Live finance-specific insights

    View All

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

    WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina

    8/6/24 7:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

    WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce

    7/31/24 2:03:34 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

    ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

    5/2/25 8:00:00 AM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix to be Acquired by electroCore

    WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ:NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. ("electroCore") (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. The shareholders of NeuroMetrix will be entitled to

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments